PureTech Presents Data About Two Promising Anti-cancer Therapies
The antibodies — LYT-200 and LYT-210 — were developed to inhibit the Galectin-9 protein and gamma delta 1 (γδ1) T-cells, respectively, both of which are increased in many solid cancers and help maintain a pro-tumoral environment. Read more. . . PureTech Health is developing two promising candidate therapies that target key immunosuppressive mechanisms in cancer and may be used against cancers that fail to respond to existing immunotherapy approaches.
